Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan and 5-FU/LV +/- Lenvatinib in Advanced Biliary System Tumors
NCT07099794Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in biliary tract cancer (BTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07099794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099794.